CTLA4 and melanoma: In the absence of an appropriate ICI-based colon cancer dataset, we hope that combined with different immunotherapy regimens (anti-PD1/L1 or anti-CTLA-4) across different malignancies (Melanoma and Urothelial cancer) to verify the effects of m6Sig score could further strengthen our conclusion.